Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYN | P07948 | 14/20 | 0.56 |
| ▸ | BTK | Q06187 | 10/20 | 0.56 |
| ▸ | SRC | P12931 | 13/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17119635 | 0.84 | BTK (0.69) | LYNBTKSRC | |
| SCHEMBL17119657 | 0.80 | LYN (0.59) | LYNBTKSRC | |
| SCHEMBL17119622 | 0.79 | SRC (0.53) | LYNBTKSRC | |
| SCHEMBL17119651 | 0.79 | BTK (0.70) | LYNBTKSRC | |
| SCHEMBL16963446 | 0.74 | BTK (0.63) | LYNBTKSRC | |
| SCHEMBL17119627 | 0.73 | LYN (0.51) | LYNBTKSRC | |
| SCHEMBL17119663 | 0.73 | BTK (0.48) | LYNBTKSRCUSP2CYP1A2 | |
| SCHEMBL16964198 | 0.73 | LYN (1.00) | LYNBTKSRC | |
| SCHEMBL17119703 | 0.72 | BTK (0.66) | LYNBTKSRC | |
| SCHEMBL17119632 | 0.72 | BTK (0.68) | LYNBTKSRCPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714247-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714247-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | LYN 330/4885BTK 245/4885SRC 161/4885 |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | LYN 330/4885BTK 245/4885SRC 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.